News

A combination therapy of endothelin receptor antagonists (ERA) plus phosphodiesterase-5 inhibitors (PDE5i) — two different agents that induce blood vessels’ widening and relaxation —improves exercise capacity, and reduces the risk of death and disease worsening in people with pulmonary arterial hypertension (PAH), a review study finds. The…

A Phase 2 clinical trial for levosimendan, a potential treatment for pulmonary hypertension (PH) and heart failure with preserved ejection fraction (PH-HFpEF), will soon have three more active sites for participant enrollment, Tenax Therapeutics announced. There now are 12 clinical sites that have initiated the study, and…

Developing gene therapies for rare diseases is one thing. Creating gene-edited “designer babies” is quite another. German legal expert Timo Minssen outlined the potentially explosive ethical landmines surrounding such issues during a recent talk at the New York Genome Center. Minssen directs the Center for Advanced Studies in…

The levels of survivin protein in the blood may help determine if surgery to treat pulmonary arterial hypertension (PAH) will be successful in people with congenital heart disease (CHD), according to new research. Findings in a rat model of PAH also suggest that the amount of survivin…

Disrupting the vascular remodeling feedback signaling loop mediated by CD146-HIF-1α can effectively prevent the development of pulmonary hypertension (PH) in mice, a study found. This suggests that medicines that could target CD146-HIF-1α signals may represent a potential strategy to treat pulmonary arterial hypertension…

People who were born prematurely, especially in recent years, are more likely to develop pulmonary arterial hypertension (PAH) later in life, a study says. The findings of the study, “Increased risk of pulmonary hypertension following premature birth,” were published in the journal BMC Pediatrics. PAH is a rare,…

Blood levels of uric acid may be a predictive biomarker of pulmonary arterial hypertension (PAH) in people with scleroderma, according to a recent study. The levels of this normal body waste product, formed when chemicals called purines break down, also may be a biomarker for disease…

Imagine living your whole life with a painful disease so rare that only 25 others worldwide have what you have. And that you’re one of just six such people who’ve made it to adulthood. Neena Nizar doesn’t have to imagine. The 41-year-old English professor at Metro Community College in Elkhorn,…

Riociguat increases the risk of death and serious adverse events in people with pulmonary hypertension (PH) associated with idiopathic interstitial pneumonia (IIP), and should not be prescribed to those patients, final results of a Phase 2 study show. The study, “Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension…

A rise in the volume of red blood cells may help to identify people with chronic obstructive pulmonary disease who are at risk of also developing pulmonary hypertension, a study from China reports. It also may potentially serve as a a cost-effective biomarker for PH secondary…

Patients with group 2 pulmonary hypertension — those with PH due to left heart disease — show increased platelet respiration, which is associated with worse right ventricular function, according to new research. The study, “Alterations in platelet bioenergetics in Group 2 PH-HFpEF patients,” was published in…

A pulmonary hypertension (PH) patient has become the 1,000th recipient of a lung transplant at the University of Washington (UW) Medicine, the hospital recently announced. UW Medicine, the only institution in the Pacific Northwest that offers lung transplants, is the 11th in the United States to hit this…